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Abstract. Background/Aim: Very few studies of anticancer
activity of azulene amides led us to investigate the
cytotoxicity of 21 N-alkylazulene-1-carboxamides introduced
either with 3-methyl [1-7], 7-isopropyl-3-methyl [8-14] or 
2-methoxy group [15-21]. Materials and Methods: Tumor-
specificity (TS) was calculated by the ratio of mean 50%
cytotoxic concentration (CC50) against three normal human
oral mesenchymal cells to that against four human oral
squamous cell carcinoma (OSCC) cell lines. Potency-
selectivity expression (PSE) was calculated by dividing TS
value by CC50 value against OSCC cell lines. Apoptosis-
inducing activity was evaluated by caspase-3 activation and
appearance of subG1 cell population. Results: [8-14] showed
higher TS and PSE values, than [1-7] and [15-21]. The most
active compound [8-14] induced apoptosis in C9-22 OSCC
cells at 4-times higher CC50. Quantitative structure-activity
relationship analysis of [1-14] demonstrated that their tumor-
specificity was correlated with chemical descriptors that
explain the molecular shape and hydrophobicity. Conclusion:
7-Isopropyl-3-methyl-N-propylazulene-1-carboxamide [8] can
be a potential candidate of lead compound for manufacturing
new anticancer drug. 
Azulene, an isomer of naphthalene, is well known for its
beneficial antioxidant effects. Azulene gargle has been used
to reduce the incidence of undesirable general anesthesia-
induced postoperative sore (1). Sodium azulene sulfonate, a
water-soluble derivative of azulene, inhibited the capsaicin-
induced pharyngitis in rats, possibly by its antioxidative
effect (2). Administration of 6-isopropyl-3-[4-(4-
chlorophenylsulfonylamino)butyl]azulene-1-sulfonic acid
sodium salt (KT2-962), a thromboxane A receptor antagonist,
significantly reduced the myocardial ischemia/reperfusion
injury in a dog, possibly by its direct hydroxyl radical
scavenging activity (3). Azulenic retinobenzoic acid
derivatives effectively suppressed the carcinogen-induced
neoplastic transformation of mouse fibroblast C3H/10T1/2
cells (4). Guaiazulene, a lipophilic azulene derivative which
is abundant in nature, protected rats from paracetamol-
induced hepatocytotoxicity by its antioxidant activity
(inhibition of lipid peroxidation and radical scavenging
action) (5). Guaiazulene also inhibited CYP1A2 that
participates in the formation of toxic metabolite N-acetyl-p-
benzoquinone imine (NAPQI) and the metabolic activation
of several toxic and carcinogenic compounds (6). On the
other hand, there is a limited number of studies that have
investigated the cytotoxicity of guaiazulene against human
malignant (7-9) and non-malignant cells (9, 10). 
We recently reported that among ten azulene-related
compounds, N-propylguaiazulenecarboxamide showed the
highest tumor-specificity against human oral squamous cell
carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-
4) vs. three normal human oral mesenchymal cells (gingival
fibroblast, HGF; periodontal ligament fibroblast, HPLF; pulp
cell, HPC) (10). Furthermore, quantitative structure-activity
relationship (QSAR) analysis demonstrated the tight
correlation between their tumor-specificity and hydrophobicity
and molecular shape (11). PubMed search revealed only one
study that has investigated the anticancer activity of azulene
amides (10). 
In order to obtain more tumor-selective guaiazulene
derivatives, we have synthesized a total of 21 N-alkylazulene-
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1-carboxamide where 3-methyl, 7-isopropyl-3-methyl or 2-
methoxy groups were introduced (Figure 1) and investigated
their anticancer activity using four human oral squamous cell
carcinoma (OSCC) cell lines and three normal human oral
mesenchymal cells. We also investigated the effect of these
compounds on apoptosis induction, since many anticancer
drugs have been reported to induce apoptosis in clinical cancer
tissues (12).
Materials and Methods
Materials. The following chemicals were obtained from the
indicated companies: Dulbecco’s modified Eagle’s medium
(DMEM) from GIBCO BRL (Grand Island, NY, USA); fetal bovine
serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), doxorubicin-HCl (DXR) from Sigma-Aldrich Inc.,
(St. Louis, MO, USA); dimethyl sulfoxide (DMSO), actinomycin D
(Act. D) from Wako Pure Chem. Ind., (Osaka, Japan); culture plastic
dishes and 96-well plates from Techno Plastic Products AG,
(Trasadingen, Switzerland). Protease and phosphatase inhibitors
were purchased from Roche Diagnostics (Tokyo, Japan).
Synthesis of alkylaminogroups. 3-methyl-N-propylazulene-1-
carboxamide [1], 3-methyl-N-butylazulene-1-carboxamide [2], 3-
methyl-N-pentylazulene-1-carboxamide [3], 3-methyl-N-(2-hydroxy-
ethyl)azulene-1-carboxamide [4], 3-methyl-N-(3-hydroxypropyl)
azulene-1-carboxamide [5], 3-methyl-N-(2-methoxyethyl)azulene-1-
carboxamide [6], 3-methyl-N-(3-methoxypropyl)azulene-1-carboxa-
mide [7], 7-isopropyl-3-methyl-N-propylazulene-1-carboxamide [8],
7-isopropyl-3-methyl-N-butylazulene-1-carboxamide [9], 7-isopropyl-
3-methyl-N-pentylazulene-1-carboxamide [10], 7-isopropyl-3-methyl-
N-(2-hydroxyethyl)azulene-1-carboxamide [11], 7-isopropyl-3-methyl-
N-(3-hydroxypropyl)azulene-1-carboxamide [12], 7-isopropyl-3-
methyl-N-(2-methoxyethyl)azulene-1-carboxamide [13], 7-isopropyl-
3-methyl-N-(3-methoxypropyl)azulene-1-carboxamide [14], 2-
methoxy-N-propylazulene-1-carboxamide [15], 2-methoxy-N-
butylazulene-1-carboxamide [16], 2-methoxy-N-pentylazulene-1-
carboxamide [17], 2-methoxy-N-(2-hydroxyethyl)azulene-1-carboxa-
mide [18], 2-methoxy-N-(3-hydroxypropyl)azulene-1-carboxamide
[19], 2-methoxy-N-(2-methoxyethyl)azulene-1-carboxamide [20], 2-
methoxy-N-(3-methoxypropyl)azulene-1-carboxamide [21] (structures
shown in Figure 1) were synthesized, according to previous reports
(13-17). All compounds were dissolved in DMSO at 40 mM and
stored at –20˚C before use.
Cell culture. Human normal oral cells (HGF, HPLF, HPC) cells (18)
at 12~20 population doubling level (PDL) and OSCC cell lines
(Ca9-22, HSC-2, HSC-3, HSC-4) (Riken Cell Bank, Tsukuba,
Japan) were cultured at 37˚C in DMEM supplemented with 10%
heat-inactivated FBS and antibiotics as described previously (11). 
Assay for cytotoxic activity. Cells were inoculated at 2×103 cells/0.1 ml
in a 96-microwell plate. After 48 h, the medium was replaced with 
0.1 ml of fresh medium containing different concentrations of test
compounds. Control cells were treated with the same amounts of
DMSO present in each diluent solution. Cells were incubated for 48 h
and the relative viable cell number was then determined by the MTT
method, as described previously (11). The CC50 was determined from
the dose–response curve of triplicate samples.
Calculation of tumor-specificity index (TS). TS was calculated as
the ratio of mean CC50 (HGF+HPLF+HPC) to mean CC50 (Ca9-
22+HSC-2+HSC-3+HSC-4), using seven cell lines [(D/B) in Table
I] (19), and as the ratio of CC50 (HGF) to CC50 (Ca9-22) [(C/A) in
Table I], using two cell lines derived from the gingival tissue (20).
Normal keratinocytes, which are highly sensitive to many anticancer
drugs (21), were not used in this study. 
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Figure 1. Structure of three groups of azulene amide derivatives used in this study.
Calculation of potency-selectivity expression (PSE). PSE was
calculated by dividing TS value by CC50 against tumor cells (19)
[(D/B2) ×100 and (C/A2) ×100] (Table I).
Western blot analysis. The cells were washed, lysed and their
protein extracts subjected to western blot (WB) analysis, as
described previously (11). The blots were probed with the primary
antibody [antibodies against cleaved caspase-3 (Cell Signaling
Technology Inc., Beverly, MD, USA), poly ADP-ribose polymerase
(PARP) (Cell Signaling Technology Inc.) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, Trevigen, Gaithersburg, MD,
USA), followed by incubation with a horseradish peroxidase-
conjugated secondary antibody [α-rabbit IgG (DAKO, Tokyo
Japan)]. The immune complexes were visualized using Pierce
Western Blotting Substrate Plus (Thermo Fisher Scientific). WB
results were documented and quantified using ImageQuant LAS 500
(GE Healthcare, Tokyo, Japan) (22).
Cell cycle analysis. Cells (approximately 106 cells) were harvested,
fixed with paraformaldehyde (Wako) in PBS(-), treated with
ribonuclease (RNase) A (Sigma-Aldrich Inc.), stained propidium
iodide (PI) (Wako) in the presence of 0.01% NonidetP-40 (Nakalai
Tesque Inc., Kyoto, Japan), filtered through Falcon® cell strainers
(Corning, NY, USA) and then were subjected to cell sorting (SH800
Series, SONY Imaging Products and Solutions Inc., Atsugi,
Kanagawa, Japan), as described previously (19). Cell cycle analysis
was performed with Cell Sorter Software version 2.1.2. (SONY
Imaging Products and Solution Inc.) (19).
Calculation of chemical descriptors. pCC50 (i.e., the −log CC50)
was used for the comparison of the cytotoxicity between the
compounds, since the CC50 values had a distribution pattern close
to a logarithmic normal distribution. The mean pCC50 values for
normal cells and tumor cell lines were defined as N and T,
respectively (23). The 3D-structure of each chemical structure was
Imanari et al: QSAR of Azulene Amide Derivatives
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Table I. Cytotoxicity of 21 azulene amide derivatives and doxorubicin against human oral squamous cell carcinoma cell lines and human oral
normal cells.
                                                                                                     CC50 (μM)
                            Human oral squamous cell carcinoma cell lines         Human normal oral cells                        TS                                PSE
                               (A)                                                          (B)          (C)                                      (D)                         
                           Ca9-22       HSC-2    HSC-3     HSC-4      mean       HGF     HPLF       HPC      mean      (D/B)     (C/A)     (D/B2)×100    (C/A2)×100
Group A                                                                                                                                   
1                             279           318        364         353         329         391       394         289       358         1.1        1.4              0.3                 0.5 
2                             139           169        148         111         142         265       285         162       237         1.7        1.9              1.2                 1.4 
3                              76             61          66           50           63          270       299         165       245         3.9        3.6              6.1                 4.7 
4                             388           324        400         392         376         398       396         389       395         1.0        1.0              0.3                 0.3 
5                             382           397        398         385         391         381       400         214       332         0.8        1.0              0.2                 0.3 
6                             377           370        362         344         363         363       400         170        311         0.9        1.0              0.2                 0.3 
7                             284           379        288         235         296         351       391         204       315         1.1        1.2              0.4                 0.4 
(mean)                    275           288        289         267         280         346       366         227       313         1.5        1.6              1.2                 1.1 
Group B                                                                                                                                   
8                               35             48          47           38           42          355       400         138       298         7.1       10.1           16.9               28.5 
9                              36            158         38          160          98          400       400         299       366         3.7       11.1             3.8                30.8 
10                            43            295         33          307         170         400       400         400       400         2.4        9.3              1.4                21.7 
11                            145           154        114         105         129         228       245         212       228         1.8        1.6              1.4                 1.1 
12                           137           163        112          94          127         252       283         184       240         1.9        1.8              1.5                 1.3 
13                            85            136        113         116         112         236       248         133       206         1.8        2.8              1.6                 3.3 
14                            54             96          67           74           73          146       143         115        135         1.9        2.7              2.5                 5.0 
(mean)                     76            150         75          128         107         288       303         212       268         2.9        5.6              4.2                13.1 
DXR                     10.10         1.40       3.29        0.08        3.72        344       349         209       301        80.9      34.1         2175.8            337.8 
Group C                                                                                                                                   
15                           176           144        109          82          128         285       285         319       296         2.3        1.6              1.8                 0.9 
16                           124            114         77           69           96          258       196         246       233         2.4        2.1              2.5                 1.7 
17                            53             75          81           61           67          155       183         137       158         2.3        2.9              3.5                 5.6 
18                           400           400        376         387         391         400       400         400       400         1.0        1.0              0.3                 0.3 
19                           376           400        380         393         387         400       400         400       400         1.0        1.1              0.3                 0.3 
20                           323           400        358         365         361         400       339         400       380         1.1        1.2              0.3                 0.4 
21                           235           387        283         274         295         354       349         366       356         1.2        1.5              0.4                 0.6 
(mean)                    241           274        238         233         246         322       307         324       318         1.6        1.6              1.3                 1.4 
DXR                      1.92          1.68       0.01        0.01        0.90       216.6    150.2      332.7    233.2     258.2    113.1       28586.9          5905.2 
CC50 value was determined by dose-response experiments performed in triplicate. Ca9-22, HSC-2, HSC-3 and HSC-4: Oral squamous cell carcinoma
cell lines; HGF: human gingival fibroblasts; HPLF: periodontal ligament fibroblasts; HPC: pulp cells; CC50: 50% cytotoxic concentration, DXR:
doxorubicin; TS: tumor-selectivity index; PSE: potency-selectivity expression.
drawn by Marvin Sketch ver 16 (ChemAxon, Budapest, Hungary,
http://www.chemaxon.com), and optimized by CORINA Classic
(Molecular Networks GmbH, Nürnberg, Germany) with partial
charge calculations (amber-10: EHT) in Molecular Operating
Environment (MOE) version 2018.0101 (Chemical Computing
Group Inc., Quebec, Canada) and Dragon (Dragon 7 version 7.0.2,
Kode srl., Pisa, Italy). 
Statistical analysis. Each experimental value was expressed as the
mean±standard deviation (SD) of triplicate or quadruplicate
measurements. The correlation between chemical descriptors and
cytotoxicity or tumor specificity was investigated using simple
regression analyses by JMP Pro version 14.0.0 (SAS Institute Inc.,
Cary, NC, USA). The significance level was set at p<0.05.
Results
Cytotoxicity. Twenty one azulene amides used in this study
were classified into three groups, 3-methyl-N-alkylazulene-
1-carboxamides [1-7] (Group A), 7-Isopropyl-3-methyl-N-
alkylazulene-1-carboxamides [8-14] (Group B) and 2-
methoxy-N-alkylazulene-1-carboxamides [15-21] (Group C)
(Figure 1). We compared their cytotoxic activity against four
human oral squamous cell carcinoma (OSCC) cell lines
(Ca9-22, HSC-2, HSC-3, HSC-4) and three normal oral cells
(HGF, HPLF, HPC), by comparing the 50% cytotoxic
concentration (CC50) determined from the dose-response
curve (example shown in Figure 2) (Table I). 
Generally, group B compounds showed higher cytotoxicity
against OSCC cell lines (mean CC50=107 μM) than group C
(246 μM) and group A compounds (280 μM). Among 21
compounds, [8] showed the highest cytotoxicity (CC50=42
μM), followed by [3] (63 μM) and [17] (67 μM). From the
dose-response curve, [3, 8, 17] and [9] showed cytotoxic and
cytostatic growth inhibition against four OSCC cell lines,
respectively (Figure 2). On the other hand, group A, B and C
compounds showed comparable cytotoxicity against normal
oral cells (mean CC50=313, 301 and 318 μM, respectively). 
Tumor-specificity (TS). TS was determined by dividing the
mean CC50 value towards the three normal cells by the mean
CC50 value towards the four OSCC cell lines (D/B, Table I)
or by dividing the CC50 value against HGF cells by the CC50
value against Ca9-22 cells, two cells derived from the
gingival tissue (C/ A, Table I). Among Group A, [3] showed
the highest tumor-specificity (TS=3.9 in D/B; 3.6 in C/A).
Among Group B, [8] showed the highest tumor-specificity
(TS= 7.1 in D/B; 10.1 in C/A), followed by [9] (TS=3.7, in
D/B; 11.1 in C/A). Among Group C, [17] showed the highest
tumor-specificity (TS=2.3 in D/B, 2.9 in C/A) (Table I).
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Figure 2. Cytotoxicity of 3-methyl-N-pentylazulene-1-carboxamide [3], 7-isopropyl-3-methyl-N-propylazulene-1-carboxamide [8], 7-isopropyl-3-
methyl-N-butylazulene-1-carboxamide [9] and 2-methoxy-N-pentylazulene-1-carboxamide [17] against human malignant and non-malignant cells.
Human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) and human oral normal cells (HGF, HPLF, HPC) were
treated for 48 h with the indicated concentrations of [3], [8], [9], or [17] and viable cell number was determined by the MTT method. Each value
represents mean±S.D. of triplicate assays.
PSE value. Next, the potency-selectivity expression (PSE)
value that reflects both the cytotoxicity against OSCC and
tumor-specificity was determined. [8] showed much higher
PSE value [16.9 in (D/B2) ×100; 28.5 in (C/A2) ×100)],
followed by [3] (PSE=6.1; 4.7), [9] (PSE=3.8; 30.8) and [17]
(PSE=3.5; 5.6). 
Apoptosis induction. Western blot analysis (Figure 3A)
demonstrated that among [3], [8], and [17] compounds, [8]
induced the cleavage of PARP, one of the substrates of
caspase-3, most potently, followed by [17] and [3], while
[17] induced cleavage of caspase-3 (producing active form)
most potently, followed by [8] and [3]. Dose-response study
(Figure 3B) showed that cleavage of PARP by [8] was
detected above 80 μM, while activation of capsase-3 was
detected above 160 μM, suggesting the induction of
apoptosis (24). Time course study (Figure 3C) shows that
cleavage of PARP was observed at early stage (1, 2 and 4 h
after treatment with 80 μM [8]), and declined thereafter (at
24 h).
Light microscopical observation (upper column, Figure 4)
revealed that cells were damaged and began to detach by
treatment with higher concentrations (160 or 200 μM) of all
three compounds [3, 8, 17]. Both [17] and actinomycin D
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Figure 3. Assessment of caspase-3 activation by [3], [8], or [17]. (A) Comparison between three compounds. (B) Dose-response and (C) time course
of apoptosis induction by [8]. Ca9-22 cells were incubated for 24 h with the indicated concentrations of [3], [8], or [17] or 1 μM actinomycin D
(Act D) as positive control and subjected to western blot analysis.
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Figure 4. Production of subG1 population by [3], [8], or [17]. Ca9-22 cells were incubated for 24 or 48 h with the indicated concentrations of [3],
[8], [17] or 1 μM actinomycin D (Act D) as a positive control and subjected to cell sorter analysis. 
(positive control) produced apoptotic cells (upper column,
Figure 4). Cell-cycle analysis demonstrated that [17]
increased the subG1 cell population to an extent similar with
that of actinomycin D, while [8] was slightly less potent in
apoptosis induction (lower panel, Figure 4).
Computational analysis. Since 3-methyl-N-alkylazulene-1-
carboxamides [1-7] (Group A), 7-Isopropyl-3-methyl-N-
alkylazulene-1-carboxamides [8-14] (Group B) showed a
higher tumor-specificity than 2-methoxy-N-alkylazulene-1-
carboxamides [15-21] (Group C), QSAR analysis was
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Figure 5. Determination of coefficient between chemical descriptors and cytotoxicity of 14 Group A and B compounds against tumor cells (defined
as T). The mean (pCC50 i.e., the −log CC50) values for tumor cell lines were defined as T.
performed with Group A and B compounds [1-14]. The
number of descriptors calculated from MOE and dragon was
344 and 5,255, respectively. As a result of excluding duplicate
descriptors, the number of descriptors reduced to 301 and
2,765, respectively. Among a total of 3,066 descriptors, the
top six descriptors that showed the highest correlation
coefficient (r2) to T, N and T-N are shown in Table II. 
Cytotoxicity against human OSCC cell lines was
correlated with descriptors SpMin1_Bh(m) (topological
shape) (r2=0.827, p<0.0001), BCUT_SLOGP_3 (topological
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Figure 6. Determination of coefficient between chemical descriptors and cytotoxicity of 14 Group A and B compounds against normal cells (defined
as N). The mean (pCC50 i.e., the −log CC50) values for normal cells were defined as N.
shape) (r2=0.796, p<0.0001), MATS8m (topological shape
and size) (r2=0.741, p=0.0001), H% (percentage of H atoms)
(r2=0.734, p=0.0001), Eig04_EA(ri) (topological shape and
energy) (r2=0.726, p=0.0001), AMW (average molecular
weight) (r2=0.725, p=0.0001) (Figure 5).
Cytotoxicity against human normal oral mesenchymal
cells was correlated with descriptors Depressant-50 (Drug-
like indices) (p=0.0025), Neoplastic-50 (Drug-like indices)
(p=0.0025), BCUT_SLOGP_2 (topological shape)
(r2=0.540, p=0.0027), Eig05_AEA(dm) (topological shape
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Figure 7. Determination of coefficient between chemical descriptors and tumor specificity of 14 Group A and B compounds (defined as T−N).
and dipole moment) (r2=0.514, p=0.0039), IC2 (topological
shape) (r2=0.424, p=0.0117), F10[C-O] (topological shape)
(r2=0.403, p=0.0147) (Figure 6).
Tumor specificity was correlated with descriptors vsurf_D6
(3D shape and size) (r2=0.815, p<0.0001), P_VSA_ppp_L
(topological shape and lipophilicity) (r2=0.813, p<0.0001),
E_str (3D shape and energy) (r2=0.792, p<0.0001),
PEOE_VSA_NEG (topological shape and partial charge)
(r2=0.790, p<0.0001), Q_VSA_NEG (topological shape and
partial charge) (r2=0.790, p<0.0001), Mor27u (3D shape and
size) (r2=0.789, p<0.0001) (Figure 7).
Discussion
The present study demonstrated that 7-isopropyl-3-methyl-
N-alkylazulene-1-carboxamides [8-14] (Group B) showed
slightly higher OSCC-specific cytotoxicity than 3-methyl-N-
alkylazulene-1-carboxamides [1-7] (Group A) and 2-
methoxy-N-alkylazulene-1-carboxamides [15-21] (Group C).
Among them, 7-isopropyl-3-methyl-N-propylazulene-1-
carboxamide [8] showed the highest tumor-specificity
towards OSCC over normal oral cells, based on TS and PSE
values. [8] induced apoptosis markers such as caspase-3
ANTICANCER RESEARCH 39: 3507-3518 (2019)
3516
Table II. Top six chemical descriptors that correlate with cytotoxicity to tumor cells, normal cells and tumor-specificity (having the highest r2
values).
                   Descriptor            Source                   Meaning                                Category                                                   Explanation
T            SpMin1_Bh(m)       Dragon           Topological shape                Burden eigenvalues                       Smallest eigenvalue n. 1 of Burden 
                                                                                                                                                                                    matrix weighted by mass
            BCUT_SLOGP_3       MOE             Topological shape            Adjacency and distance                  The BCUT descriptors using atomic 
                                                                                                                      matrix descriptors                 contribution to logP (using the Wildman and
                                                                                                                                                                Crippen SlogP method) instead of partial charge.
                   MATS8m            Dragon    Topological shape and size         2D autocorrelations           Moran autocorrelation of lag 8 weighted by mass
                        H%                 Dragon       Percentage of H atoms          Constitutional indices                                Percentage of H atoms
                Eig04_EA(ri)         Dragon           Topological shape            Edge adjacency indices                  Eigenvalue n. 4 from edge adjacency 
                                                                            and energy                                                                            mat. weighted by resonance integral
                      AMW               Dragon    Average molecular weight       Constitutional indices                             Average molecular weight
N             Depressant-50        Dragon            Drug-like indices                  Drug-like indices                           Ghose-Viswanadhan-Wendoloski 
                                                                                                                                                                              antidepressant-like index at 50%
                Neoplastic-50         Dragon            Drug-like indices                  Drug-like indices                           Ghose-Viswanadhan-Wendoloski 
                                                                                                                                                                              antineoplastic-like index at 50%
            BCUT_SLOGP_2       MOE             Topological shape             Adjacency and distance                   The BCUT descriptors using atomic 
                                                                                                                     matrix descriptors                           contribution to logP (using the 
                                                                                                                                                                          Wildman and Crippen SlogP method) 
                                                                                                                                                                                    instead of partial charge.
             Eig05_AEA(dm)      Dragon       Topological shape and        Edge adjacency indices                 Eigenvalue n. 5 from augmented edge 
                                                                         dipole moment                                                                   adjacency mat. weighted by dipole moment
                        IC2                 Dragon           Topological shape                Information indices                  Information Content index (neighborhood 
                                                                                                                                                                                       symmetry of 2-order)
                   F10[C-O]            Dragon           Topological shape                    2D atom pairs                   Frequency of C - O at topological distance 10
T-N              vsurf_D6              MOE             3D shape and size           Surface area, volume and                 Hydrophobic volume (8 descriptors)
                                                                                                                      shape descriptors
               P_VSA_ppp_L        Dragon           Topological shape             P_VSA-like descriptor                             P_VSA-like on potential 
                                                                        and lipophilicity                                                                       pharmacophore points, L - lipophilic
                       E_str                  MOE          3D shape and energy                Potential Energy                        Bond stretch potential energy. In the 
                                                                                                                            descriptors                            Potential Setup panel, the term enable 
                                                                                                                                                                                 (Bonded) flag is ignored, but 
                                                                                                                                                                                   the term weight is applied.
            PEOE_VSA_NEG      MOE             Topological shape                    Partial charge                     Total negative van der Waals surface area. 
                                                                       and partial charge                       descriptors                   This is the sum of the vi such that qi is negative. 
                                                                                                                                                                                 The vi are calculated using a 
                                                                                                                                                                              connection table approximation.
               Q_VSA_NEG          MOE             Topological shape          Partial charge descriptors            Total negative van der Waals surface area. 
                                                                       and partial charge                                                            This is the sum of the vi such that qi is negative. 
                                                                                                                                                                                 The vi are calculated using a 
                                                                                                                                                                              connection table approximation.
                     Mor27u              Dragon           3D shape and size             3D-MoRSE descriptors                               Signal 27/unweighted
activation (24) and production of subG1 population (25) only
at 160 μM (Figure 3), four times the CC50 (42 μM) (Table
I). On the other hand, [17], that showed lower tumor-
specificity than [8] (TS=2.3 vs. 7.1 (D/B), 2.9 vs. 10.1 (C/A);
PSE=3.5 vs. 16.9 in (D/B2)×100, 5.6 vs. 28.5 in C/A2)×100)
(Table I), activated caspase-3 and produced a higher subG1
population (Figure 4). These data suggest that induction of
tumor-specific cytotoxicity (anti-tumor activity) by [8] may
not be mediated via apoptosis induction. There are many
types of cell death, such as intrinsic and extrinsic apoptosis,
oncosis, necroptosis, parthanatos, ferroptosis, sarmoptosis,
autophagic cell death, autosis, autolysis, paraptosis,
pyroptosis, phagoptosis, and mitochondrial permeability
transition (26). Further study is required to investigate the
possibility of the involvement of necrotic cell death, such as
pyroptosis and necroptosis, in which the activation of
caspase-1, IL-1β and IL-18IL-pathways is involved (27).
QSAR analysis with 14 Group A and B compounds
demonstrated that their tumor-specificity was correlated with
molecular shape (descripted by vsurf_D6, P_VSA_ppp_L,
E_str, PEOE_VSA_NEG, Q_VSA_NEG, Mor27u) and
lipophilicity (descripted by P_VSA_ppp_L) (Table II). We
also reported previously that tumor-specificity of ten N-
alkylguaiazulenecarboxamides was correlated with molecular
shape (descripted by vsurf_ID1, vsurf_ID5, vsurf_ID4,
vsurf_CW4, vsurf_ID3, vsurf_CW3) and hydrophobicity
(descripted by vsurf_ID1, vsurf_ID5, vsurf_ID4, vsurf_ID3)
(11). These data suggest that the antitumor-potential of
guaiazulenes can be estimated by their molecular shape and
hydrophobicity. By closer inspection, [9] (100~400 μM) and
[17] (13~100 μM) were found to stimulate the growth of
normal oral cells. The biological significance of this hormetic
growth stimulation (28) remains to be investigated.
[8] and [9] have similar chemical structure to guaiazulene
(1,4-dimethyl-7-isopropylazulene), all of them having isopropyl
group in seven-membered ring and methyl group at the different
positions. As far as we know only two studies have been
published on the anticancer activity against OSCC (8, 29). More
tumor-specific derivatives of [8] as a lead compound are being
synthesized to examine their anti-cancer effects. 
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Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts
Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001
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December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council
of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately
trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos
and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.
Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.
Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html
In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the
online submission system should be addressed to: email: journals@iiar-anticancer.org
Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections
of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the
acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer
Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs
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